First nine-month complete invasive assessment (angiography, IVUS, and OCT) of the novel NEVO sirolimus-eluting stent with biodegradable polymer.
At present, percutaneous coronary intervention with drug-eluting stent (DES) implantation represents the default strategy to treat coronary artery disease in many institutions around the world. However, concerns regarding long-term safety of first-generation DES have prompted the development of novel DES systems such as the NEVO (Cordis Corporation, Johnson & Johnson, Warren, NJ) sirolimus-eluting stent with biodegradable polymer and reservoir technology. In the current report, we present, for the first time, a complete midterm invasive assessment of a patient treated with this novel device in the Res-Elution I study.
Abizaid
Alexandre
A
Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. aabizaid@uol.com.br
Costa
J Ribamar
JR
Feres
Fausto
F
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D001672:Biocompatible Materials; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000628:therapy*; D023903:Coronary Restenosis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D054855:Drug-Eluting Stents; D006801:Humans; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage*; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D001672:Biocompatible Materials; D002317:Cardiovascular Agents; D020123:Sirolimus